Scleroderma, also known as sclerosis is a rare, chronic disorder involving overproduction and accumulation of collagen in the tissues of the body. Scleroderma majorly affects skin but is not limited to the skin and also affects several major internal organs such as kidney, lungs, heart, and others. The condition wherein thickening of tissues is seen in the skin as well as internal organs is known as systemic scleroderma. Systemic scleroderma causes tightening and hardening of patches of skin which may lead to restricted movement of the affected area. The number and size of patches may vary depending upon the severity of systemic scleroderma disease. Raynaud's disease which causes pain and numbness in fingers or toes in response to cold temperature, is one of the earliest signs of systemic scleroderma. Systemic scleroderma may affect gastrointestinal tract and lead to cramps, diarrhea, constipation, heartburn, and lack of proper absorption of nutrients from the food into the body cells. Systemic scleroderma can become life-threatening if untreated at the right time.
The global systemic scleroderma treatment market is estimated to be valued at US$ 1,520.1 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).
Figure 1. Global Systemic Scleroderma Treatment Market Share (%), By Region, 2021
The increasing prevalence of scleroderma is expected to drive the growth of the global systemic scleroderma treatment market over the forecast period.
For instance, according to an article published by the Journal of Managed Care & Specialty Pharmacy in December 2020, the prevalence of systemic scleroderma increased from 7.8 per 100,000 in 2011 to 24.3 per 100,000 people in 2016 in the U.S and is expected to further increase in the near future.
|Base Year:||2020||Market Size in 2021:||US$ 1,520.1 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||4.2 %||2028 Value Projection:||US$ 2,027.4 Mn|
Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals, Actelion Pharmaceuticals Ltd., Allergan, F. Hoffmann-La Roche Ltd., Biogen, Novartis AG, AstraZeneca, Celgene corporation, Ono pharmaceutical co. Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Pfizer Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Sanofi, and Argentis Pharmaceuticals, LLC
|Restraints & Challenges:||
Figure 2. Global Systemic Scleroderma Treatment Market Value (US$ Mn), By Drug Class, 2021
The increasing research and development activities for the development of novel therapeutics for the treatment of scleroderma is expected to drive the market growth over the forecast period.
For instance, according to study results published in the Journal of Rheumatology in March 2017, Imatinib Mesylate (Gleevec), an oral chemotherapy medication showed positive results to be used in the treatment of diffuse cutaneous systemic sclerosis. Imatinib Mesylate (Gleevec) is manufactured by Novartis Pharmaceuticals, a Switzerland based pharmaceutical company.
Key players operating in the market are focusing on submitting application for approval of drugs therapy for the treatment of scleroderma, which is expected to drive growth of the global systemic scleroderma treatment market over the forecast period.
For instance, in September 2019, Boehringer Ingelheim International GmbH, a Germany based pharmaceutical company received the U.S. Food and Drug Administration Approval for Ofev (nintedanib), a drug which is to be used to treat patients with systemic sclerosis associated interstitial lung disease.
Global Systemic Scleroderma Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was declared as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the globe infecting over 211 million population leading to more than 4.4 million deaths as of August 22, 2021. The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. However, recent studies have shown association of COVID-19 with systemic scleroderma and this is expected to show a positive result on the overall growth of the scleroderma treatment market during the pandemic.
For instance, according to a research study conducted in Italy and published by the Lancet Rheumatology journal in March 2021, higher prevalence of COVID-19 has been reported in patients suffering with systemic sclerosis related interstitial lung involvement than in those without it. Moreover, the same study reports high death rate among COVID-19 patients suffering from systemic sclerosis and concludes that risk of severe COVID-19 is high in patients suffering from systemic sclerosis.
Global Systemic Scleroderma Treatment Market - Restraint
The lack of a standard framework for evaluating systemic scleroderma therapeutics and clinical trial failure are the factors that are expected to hinder growth of the global systemic scleroderma treatment market over the forecast period. For instance, in September 2020, Lenabasum, an oral cannabinoid-2 agonist manufactured by Corbus Pharmaceuticals Holdings Inc., a U.S. based clinical stage pharmaceutical company failed to show positive phase III efficacy in treatment of diffuse cutaneous systemic sclerosis despite showing benefits in phase II clinical trial results.
Major players operating in the global systemic scleroderma treatment market include Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals, Actelion Pharmaceuticals Ltd., Allergan, F. Hoffmann-La Roche Ltd., Biogen, Novartis AG, AstraZeneca, Celgene Corporation, Ono pharmaceutical co. Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Pfizer Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Sanofi, and Argentis Pharmaceuticals, LLC
Scleroderma is a chronic condition which commonly affects the skin and connective tissue. Scleroderma is an autoimmune disorder wherein the immune system of the body produces extra collagen protein which gets deposited in the tissues and causes hardening of skin. Collagen is a fibrous protein which is found abundantly in the body to provide strength and structure to the body. The two major forms of scleroderma include localized and systemic. In localized scleroderma, only the skin is affected and not any organs while in systemic scleroderma, the skin and the underlying tissues under it are affected. Systemic scleroderma affects blood vessels and major organs of the body such as heart, lungs, kidneys, gastrointestinal tract, and others. Systemic scleroderma can be classified into three major types namely, limited systemic sclerosis, diffused systemic sclerosis, and systemic sclerosis sine scleroderma. Limited scleroderma is one of the most common type of systemic scleroderma wherein, the hardening effect of the disease is limited to fingers and it is less likely to cause internal organ damage. In diffused systemic sclerosis, body parts such as fingers, hands, arms, anterior trunk, legs, and face are affected. Diffused systemic sclerosis also affects internal organs such as heart and lungs. In systemic sclerosis sine scleroderma, no skin thickening is seen but internal organs such as heart, kidney, and lungs may get severely damaged.
The increasing prevalence of scleroderma, rising research and development activities for the development of novel therapeutics for the treatment of scleroderma, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global systemic scleroderma treatment market over the forecast period.
For instance, according to a review article published by the Rheumatology Journal of the British Society for Rheumatology in February 2021, the pooled global prevalence of scleroderma was estimated to be 17.6 per 100,000 people in 2021 and is expected to increase in the near future.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.